Vmbook Online ordering

Xenoport Inc

I am not a stock trading expert, but I can provide you with some general information about Xenoport, Inc., a public company that was previously listed on the NASDAQ stock exchange in the USA.

Xenoport, Inc. was a biopharmaceutical company focused on developing and commercializing medicines to improve the lives of patients with neurological disorders. The company's lead product was Horizant (generic name: gabapentin enacarbil), a treatment for restless legs syndrome and postherpetic neuralgia. Horizant was initially approved by the FDA in 2010 and 2011, respectively.

Xenoport was founded in 1994 and headquartered in Milpitas, California. The company was acquired by Arbor Pharmaceuticals LLC in May 2016. Soon after the acquisition, Arbor decided to delist Xenoport's common stock from the NASDAQ and operate Xenoport's business as a privately-held subsidiary. Since then, detailed information about Xenoport's business is not readily available in public sources.

Investors who previously held shares of Xenoport were provided with information about the acquisition and were entitled to receive the merger consideration from Arbor Pharmaceuticals. As of now, the publicly-available information about Xenoport is limited.